SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

Home・Akciju saraksts・Pharming Group NV

P
Pharming Group NV

Slēgts

1.415 -2.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.391

Max

1.45

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 7.5M
Pārdošana	4.1M 97M
EPS	0.009
Peļņas marža	7.758
Darbinieki	404

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-43M 954M
Iepriekšējā atvēršanas cena	3.9
Iepriekšējā slēgšanas cena	1.415

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. nov. 22:42 UTC

Tirgus saruna

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 21:47 UTC

Tirgus saruna

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

2025. g. 21. nov. 21:43 UTC

Tirgus saruna

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

2025. g. 21. nov. 20:18 UTC

Tirgus saruna

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

2025. g. 21. nov. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

2025. g. 21. nov. 19:48 UTC

Tirgus saruna

Precious Metals Fall for the Week -- Market Talk

2025. g. 21. nov. 19:44 UTC

Peļņas

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

2025. g. 21. nov. 19:37 UTC

Tirgus saruna

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

2025. g. 21. nov. 19:20 UTC

Tirgus saruna

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

2025. g. 21. nov. 18:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

2025. g. 21. nov. 18:37 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

2025. g. 21. nov. 18:34 UTC

Tirgus saruna

Peļņas

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

2025. g. 21. nov. 18:28 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 18:03 UTC

Tirgus saruna

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Intuit Seen on Path to Increase Growth -- Market Talk

2025. g. 21. nov. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 17:05 UTC

Tirgus saruna

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

2025. g. 21. nov. 16:56 UTC

Tirgus saruna

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

2025. g. 21. nov. 16:47 UTC

Tirgus saruna

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

2025. g. 21. nov. 16:35 UTC

Iegādes, apvienošanās, pārņemšana

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

2025. g. 21. nov. 16:09 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. nov. 15:23 UTC

Tirgus saruna

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

2025. g. 21. nov. 15:17 UTC

Tirgus saruna

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharming Group NV — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.